FDA Approves Zepbound for 84 Million U.S. Sleep Apnea Cases as CPAP Adherence Lags
Updated
Updated · Men's Health · Jul 21
FDA Approves Zepbound for 84 Million U.S. Sleep Apnea Cases as CPAP Adherence Lags
3 articles · Updated · Men's Health · Jul 21
Summary
Zepbound won FDA approval in December 2024 as the first prescription drug for overweight adults with moderate to severe obstructive sleep apnea, adding a non-device option beyond CPAP.
84 million U.S. adults are estimated to have obstructive sleep apnea, with about 80% undiagnosed, while untreated cases raise risks including heart problems, cognitive issues and early death.
CPAP remains the gold-standard therapy, but adherence is weak: a 2025 study of 1,907 users found only 45% met high-adherence standards, and another study put minimum adherence at 38% after three months.
Other alternatives include Inspire implants—used more than 100,000 times worldwide—custom mandibular devices that cut severe-case breathing disruptions by 73% in a 2025 study, and Apnimed's pill, which showed a 56% reduction in phase 3 trials.
A top CPAP maker is banned for safety failures. Are new drugs the only trustworthy solution left for millions with sleep apnea?
A new pill may soon treat sleep apnea without a mask. Could this breakthrough finally make the unpopular CPAP machine a medical relic?
Zepbound’s Landmark FDA Approval for Obesity-Related Sleep Apnea: Addressing Unmet Needs and Shaping the Future of OSA Treatment
Overview
In December 2024, the FDA approved Zepbound (tirzepatide) as the first medication specifically for adults with obesity and moderate-to-severe obstructive sleep apnea (OSA). Clinical trials showed that patients experienced significant improvements in their sleep apnea symptoms after 52 weeks of treatment, with benefits often seen after weight loss occurred. This highlights the strong link between obesity and OSA severity, suggesting that Zepbound works by helping patients lose weight. Physicians prescribe Zepbound in gradually increasing doses, following a 4-week schedule, to ensure safe and effective treatment for this challenging condition.